| Mar 26 | Mar 25 | Mar 24 | Dec 22 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 52.27M | $ 36.00M | $ 34.81M | $ 35.41M | $ 37.24M |
| Gross Profit | $ 2.32M | $ 8.98M | $ 12.04M | $ 23.10M | $ 18.69M |
| Operating Income | $ -9.35M | $ -11.18M | $ -1.80M | $ 8.93M | $ 9.49M |
| EBITDA | $ 6.80M | $ -2.02M | $ 16.77M | $ 15.03M | $ 12.80M |
| Net Income | $ -18.31M | $ -22.44M | $ 4.40M | $ 10.92M | $ 4.99M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 5.07M | $ 4.62M | $ 8.72M | $ 5.93M | $ 6.47M |
| Total Assets | $ 120.31M | $ 136.97M | $ 149.56M | $ 120.52M | $ 83.70M |
| Total Debt | $ 34.97M | $ 39.52M | $ 38.60M | $ 38.15M | $ 14.10M |
| Net Debt | $ 29.90M | $ 34.89M | $ 29.88M | $ 32.22M | $ 7.64M |
| Total Liabilities | $ 65.04M | $ 61.23M | $ 54.58M | $ 48.60M | $ 24.31M |
| Stockholders' Equity | $ 55.27M | $ 75.74M | $ 94.98M | $ 71.92M | $ 59.39M |
| Cash Flow | |||||
| Free Cash Flow | $ 8.29M | $ 1.82M | $ 1.69M | $ -2.94M | $ -7.10M |
| Operating Cash Flow | $ 11.92M | $ 3.29M | $ 4.42M | $ 5.92M | $ 11.68M |
| Investing Cash Flow | $ -5.76M | $ -5.44M | $ -4.82M | $ -30.31M | $ -27.10M |
| Financing Cash Flow | $ -5.69M | $ -1.95M | $ 3.19M | $ 23.86M | $ 20.14M |
Vext Science (VEXTF)
OTHER OTC:VEXTF
